iSpecimen (NASDAQ:ISPC) vs. PACS Group (NYSE:PACS) Head to Head Comparison

PACS Group (NYSE:PACS) and iSpecimen (NASDAQ:ISPC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation and Earnings

This table compares PACS Group and iSpecimen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$4.09 billion	1.50	$55.76 million	$1.05	37.20
iSpecimen	$9.29 million	0.36	-$12.50 million	($7.89)	-0.04

PACS Group has higher revenue and earnings than iSpecimen. iSpecimen is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PACS Group and iSpecimen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	1	1	5	0	2.57
iSpecimen	1	0	0	0	1.00

PACS Group currently has a consensus price target of $39.40, suggesting a potential upside of 0.88%. Given PACS Group’s stronger consensus rating and higher probable upside, analysts plainly believe PACS Group is more favorable than iSpecimen.

Volatility & Risk

PACS Group has a beta of -0.74, suggesting that its share price is 174% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Profitability

This table compares PACS Group and iSpecimen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PACS Group	3.29%	21.39%	3.09%
iSpecimen	-343.86%	-531.78%	-147.74%

Institutional & Insider Ownership

13.6% of iSpecimen shares are owned by institutional investors. 70.4% of PACS Group shares are owned by insiders. Comparatively, 12.2% of iSpecimen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

PACS Group beats iSpecimen on 12 of the 14 factors compared between the two stocks.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.